BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $16.30.

BCRX has been the topic of several research reports. Wedbush upped their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 30th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America lifted their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $7.15 on Tuesday. The stock’s fifty day moving average price is $8.11 and its two-hundred day moving average price is $8.70. BioCryst Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $11.31. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -39.72, a P/E/G ratio of 1.44 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same period in the prior year, the company posted ($0.06) EPS. The firm’s quarterly revenue was up 49.5% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GAMMA Investing LLC raised its holdings in BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter worth $62,000. Family Legacy Financial Solutions LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter worth $72,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter worth $79,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.